Our results showed that HOXA11-AS could promote the proliferation and migration of ovarian cancer cells by inhibiting intracellular autophagy levels, and promote cisplatin resistance of ovarian cancer cells, so as to provide the evidence that HOXA11-AS may be a therapeutic target for ovarian cancer. This evidence concerns the gene HOXA11 and ovarian carcinoma.